Pfizer Inc. (NYSE:PFE) Stock Position Lowered by Institutional & Family Asset Management LLC

Institutional & Family Asset Management LLC trimmed its position in shares of Pfizer Inc. (NYSE:PFEGet Rating) by 7.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 15,322 shares of the biopharmaceutical company’s stock after selling 1,151 shares during the period. Institutional & Family Asset Management LLC’s holdings in Pfizer were worth $905,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Bank OZK grew its holdings in shares of Pfizer by 0.3% during the fourth quarter. Bank OZK now owns 68,883 shares of the biopharmaceutical company’s stock worth $4,067,000 after purchasing an additional 195 shares in the last quarter. TimeScale Financial Inc. grew its holdings in shares of Pfizer by 2.9% during the fourth quarter. TimeScale Financial Inc. now owns 6,978 shares of the biopharmaceutical company’s stock worth $412,000 after purchasing an additional 196 shares in the last quarter. Bath Savings Trust Co grew its holdings in shares of Pfizer by 0.5% during the fourth quarter. Bath Savings Trust Co now owns 39,684 shares of the biopharmaceutical company’s stock worth $2,344,000 after purchasing an additional 200 shares in the last quarter. Fruth Investment Management grew its holdings in shares of Pfizer by 0.7% during the fourth quarter. Fruth Investment Management now owns 29,313 shares of the biopharmaceutical company’s stock worth $1,730,000 after purchasing an additional 200 shares in the last quarter. Finally, Winfield Associates Inc. grew its holdings in shares of Pfizer by 0.9% during the fourth quarter. Winfield Associates Inc. now owns 21,557 shares of the biopharmaceutical company’s stock worth $1,273,000 after purchasing an additional 200 shares in the last quarter. 66.50% of the stock is currently owned by institutional investors.

A number of analysts recently weighed in on PFE shares. Zacks Investment Research downgraded Pfizer from a “buy” rating to a “hold” rating and set a $52.00 target price for the company. in a research report on Tuesday, February 15th. Berenberg Bank set a $50.00 target price on Pfizer in a research report on Thursday, May 19th. Citigroup boosted their target price on Pfizer from $46.00 to $57.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 5th. Morgan Stanley assumed coverage on Pfizer in a research report on Wednesday, April 6th. They issued an “equal weight” rating and a $55.00 price objective for the company. Finally, The Goldman Sachs Group set a $51.00 target price on shares of Pfizer in a report on Wednesday, May 4th. Eleven investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $57.00.

In other Pfizer news, SVP Jennifer B. Damico sold 4,000 shares of the company’s stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $50.50, for a total value of $202,000.00. Following the completion of the sale, the senior vice president now owns 15,064 shares in the company, valued at $760,732. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP William R. Carapezzi, Jr. sold 32,908 shares of Pfizer stock in a transaction that occurred on Thursday, May 12th. The shares were sold at an average price of $50.00, for a total value of $1,645,400.00. Following the sale, the executive vice president now directly owns 38,146 shares in the company, valued at approximately $1,907,300. The disclosure for this sale can be found here. 0.05% of the stock is currently owned by corporate insiders.

Shares of NYSE:PFE traded up $0.52 during midday trading on Wednesday, reaching $53.93. 567,152 shares of the company’s stock traded hands, compared to its average volume of 30,933,111. The company has a market cap of $302.60 billion, a price-to-earnings ratio of 12.20, a P/E/G ratio of 0.61 and a beta of 0.76. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.13 and a current ratio of 1.39. Pfizer Inc. has a one year low of $38.47 and a one year high of $61.71. The stock has a 50 day moving average of $51.45 and a 200 day moving average of $52.24.

Pfizer (NYSE:PFEGet Rating) last posted its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 EPS for the quarter, missing analysts’ consensus estimates of $1.66 by ($0.04). The firm had revenue of $25.66 billion for the quarter, compared to analysts’ expectations of $24.73 billion. Pfizer had a net margin of 26.97% and a return on equity of 38.29%. The firm’s revenue was up 76.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.93 EPS. Sell-side analysts predict that Pfizer Inc. will post 6.63 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 10th. Investors of record on Friday, May 13th will be given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 2.97%. The ex-dividend date is Thursday, May 12th. Pfizer’s dividend payout ratio (DPR) is presently 36.70%.

Pfizer Company Profile (Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Featured Stories

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.